181 related articles for article (PubMed ID: 16041541)
1. Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment.
Yamaji K; Nabeshima S; Murata M; Chong Y; Furusyo N; Ikematsu H; Hayashi J
Cancer Immunol Immunother; 2006 Apr; 55(4):394-403. PubMed ID: 16041541
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines.
Murata M; Nabeshima S; Kikuchi K; Yamaji K; Furusyo N; Hayashi J
Cytokine; 2006 Feb; 33(3):121-8. PubMed ID: 16522372
[TBL] [Abstract][Full Text] [Related]
3. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection.
Jinushi M; Takehara T; Tatsumi T; Kanto T; Groh V; Spies T; Suzuki T; Miyagi T; Hayashi N
J Immunol; 2003 Nov; 171(10):5423-9. PubMed ID: 14607946
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(5):457-68. PubMed ID: 17147054
[TBL] [Abstract][Full Text] [Related]
5. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo.
Sharara AI; Perkins DJ; Misukonis MA; Chan SU; Dominitz JA; Weinberg JB
J Exp Med; 1997 Nov; 186(9):1495-502. PubMed ID: 9348307
[TBL] [Abstract][Full Text] [Related]
6. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
7. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
Kashiwagi K; Furusyo N; Kubo N; Nakashima H; Nomura H; Kashiwagi S; Hayashi J
J Infect Chemother; 2003 Dec; 9(4):333-40. PubMed ID: 14691655
[TBL] [Abstract][Full Text] [Related]
8. Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection.
Zhang S; Kodys K; Li K; Szabo G
Gastroenterology; 2013 Feb; 144(2):414-425.e7. PubMed ID: 23089201
[TBL] [Abstract][Full Text] [Related]
9. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment.
Shapiro S; Gershtein V; Elias N; Zuckerman E; Salman N; Lahat N
Clin Exp Immunol; 1998 Oct; 114(1):55-60. PubMed ID: 9764603
[TBL] [Abstract][Full Text] [Related]
10. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
[TBL] [Abstract][Full Text] [Related]
12. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
Tokumoto Y; Hiasa Y; Uesugi K; Watanabe T; Mashiba T; Abe M; Kumagi T; Ikeda Y; Matsuura B; Onji M
J Infect Dis; 2012 Apr; 205(7):1121-30. PubMed ID: 22357660
[TBL] [Abstract][Full Text] [Related]
13. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
[TBL] [Abstract][Full Text] [Related]
14. Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon.
Yoneyama K; Yamaguchi M; Kiuchi Y; Morizane T; Shibata M; Mitamura K
Intervirology; 2002; 45(1):11-9. PubMed ID: 11937766
[TBL] [Abstract][Full Text] [Related]
15. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
Hu X; Luo H; Tan G; Li Y; Qin B
BMC Gastroenterol; 2023 May; 23(1):163. PubMed ID: 37208599
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
Wang T; Blatt LM; Seiwert SD
J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C.
Byrnes AA; Li DY; Park K; Thompson D; Mocilnikar C; Mohan P; Molleston JP; Narkewicz M; Zhou H; Wolf SF; Schwarz KB; Karp CL
J Leukoc Biol; 2007 Mar; 81(3):825-34. PubMed ID: 17148690
[TBL] [Abstract][Full Text] [Related]
18. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1.
Tian S; Hui X; Fan Z; Li Q; Zhang J; Yang X; Ma X; Huang B; Chen D; Chen H
FASEB J; 2014 Aug; 28(8):3528-39. PubMed ID: 24769671
[TBL] [Abstract][Full Text] [Related]
19. Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.
Katayama K; Kasahara A; Sasaki Y; Kashiwagi T; Naito M; Masuzawa M; Katoh M; Yoshihara H; Kamada T; Mukuda T; Hijioka T; Hori M; Hayashi N
J Viral Hepat; 2001 May; 8(3):180-5. PubMed ID: 11380795
[TBL] [Abstract][Full Text] [Related]
20. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
